Diffusion of a new drug: A comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands

Clinical Therapeutics

Volumn 32, Issue 1, 2010, Pages 108-118

  Pechlivanoglou, Petros ^a   Vehof, Jelle ^b   van Agthoven, Michel ^c   de Jong van den Berg, Lolkje T W ^a   Postma, Maarten J ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Janssen Cilag BV Netherlands   (Netherlands)

Author keywords

depot; drug diffusion; persistence; risperidone; treatment complexity

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; ECONOMICS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MASS COMMUNICATION; NETHERLANDS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; SCHIZOPHRENIA; STATISTICS; SURVIVAL; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DIFFUSION OF INNOVATION; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; MEDICATION ADHERENCE; NETHERLANDS; PATIENT ACCEPTANCE OF HEALTH CARE; PHYSICIAN'S PRACTICE PATTERNS; RISPERIDONE; SCHIZOPHRENIA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 77952303872     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.01.008     Document Type: Article

References (31)

1. Kyle, M, The role of firm characteristics in pharmaceutical product launches. RAND J Econ. 37 (2006), 602–618.
2. Desiraju, R, Nair, H, Chintagunta, P, Diffusion of new pharmaceutical drugs in developing and developed nations. Int J Res Market 21 (2004), 341–357.
3. Chintagunta, P, Jiang, R, Jin, GZ, Information, learning, and drug diffusion: The case of cox-2 inhibitors. NBER Working Paper No. 14252, August 2008 http://papers.nber.org/papers/w14252.pdf Accessed December 9, 2009.
4. Olivier, P, Montastruc, JL, The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Pharmacoepidemiol Drug Saf. 15 (2006), 808–812.
5. Hamann, J, Adjan, B, Leucht, S, Kissling, W, Psychiatric decision making in the adoption of a new antipsychotic in Germany. Psychiatr Serv. 57 (2006), 700–703.
6. Valenstein, M, McCarthy, JF, Ignacio, RV, et al. Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system. Psychiatr Serv. 57 (2006), 70–76.
7. Domino, ME, Frank, RG, Rosenheck, R, The diffusion of new antipsychotic medications and formulary policy. Schizophr Bull. 29 (2003), 95–104.
8. Goldner, EM, Hsu, L, Waraich, P, Somers, JM, Prevalence and incidence studies of schizophrenic disorders: A systematic review of the literature. Can J Psychiatry 47 (2002), 833–843.
9. Murray, C, Lopez, A, The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020, 1996, Harvard University Press, Cambridge, Mass.
10. Fenton, WS, McGlashan, TH, Victor, BJ, Blyler, CR, Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry 154 (1997), 199–204.
11. Levinson, DF, Umapathy, C, Musthaq, M, Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 156 (1999), 1138–1148.
12. Gerlach, J, The continuing problem of extrapyramidal symptoms: Strategies for avoidance and effective treatment. J Clin Psychiatry 60:Suppl 23 (1999), 20–24.
13. Lindenmayer, JP, Czobor, P, Volavka, J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psych. 160 (2003), 290–296.
14. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004), 596–601.
15. Patel, MX, David, AS, Why aren't depot antipsychotics prescribed more often and what can be done about it?. Adv Psych Treat. 11 (2005), 203–211.
16. Möller, HJ, Long-acting injectable risperidone for the treatment of schizophrenia: Clinical perspectives. Drugs. 67 (2007), 1541–1566.
17. Schirm, E, Monster, TB, de Vries, R, et al. How to estimate the population that is covered by community pharmacies? An evaluation of two methods using drug utilisation information. Pharmacoepidemiol Drug Saf. 13 (2004), 173–179.
18. Rijcken, C, Tobi, H, Vergouwen, A, de Jong-van den Berg, LT, Refill rate of antipsychotic drugs: An easy and inexpensive method to monitor patients' compliance by using computerised pharmacy data. Pharmacoepidemiol Drug Saf. 13 (2004), 365–370.
19. Manji, HK, Bowden, CL, Belmaker, RH, (eds.) Bipolar Medications: Mechanisms of Action, 1st ed., 2000, American Psychiatric Press, Washington, DC.
20. Limbrunner, JF, Vogel, RM, Brown, LC, Estimation of harmonic mean of a lognormal variable. J Hydrologic Eng. 5 (2000), 59–66.
21. Sokal, RR, Rohlf, FJ, Biometry: The Principles and Practice of Statistics in Biological Research, 3rd ed., 1995, W.H. Freeman, New York, NY.
22. Hardy, MA, Bryman, A, (eds.) Handbook of Data Analysis, 2004, Sage Publications, London, UK; Thousand Oaks, Calif.
23. Peng, Y, Dear, KB, Denham, JW, A generalized F mixture model for cure rate estimation. Stat Med. 17 (1998), 813–830.
24. Chakos, MH, Glick, ID, Miller, AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv. 57 (2006), 1094–1101.
25. Health Insurance Executive Board. Dutch Pharmacoeconomic Guidelines 2008 [in Dutch], 2008, Health Insurance Executive Board, Amstelveen, the Netherlands.
26. Williams, R, Kopala, L, Malla, A, et al. Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia. Acta Psychiatr Scand Suppl. 430 (2006), 12–21.
27. Martinussen, T, Scheike, T, Dynamic Regression Models for Survival Data, 2006, Springer, New York, NY.
28. Rosenbaum, PR, Rubin, DB, Reducing bias in observational studies using subclassification on propensity score. J Am Stat Assoc. 79 (1984), 516–524.
29. Rainer, MK, Risperidone long-acting injection: A review of its long term safety and efficacy. Neuropsychiatr Dis Treat. 4 (2008), 919–927.
30. Niaz, OS, Haddad, PM, Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand. 116 (2007), 36–46.
31. Paton, C, Okocha, C, Risperidone long-acting injection: The first 50 patients. Psychiatr Bull. 28 (2004), 12–14.